Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0PA6K
|
|||
| Former ID |
DNC000909
|
|||
| Drug Name |
LY53857
|
|||
| Synonyms |
UNII-OK43YC00I7; OK43YC00I7; LY53857; LY 53857; LY-53857 free base; Biomol-NT_000165; AC1MHY97; Lopac0_000721; GTPL183; BPBio1_000595; CHEMBL1356280; CCG-204806; NCGC00163176-01; LY-53,857; LS-187317; Ergoline-8beta-carboxylic acid, 1-isopropyl-6-methyl-, 2-hydroxy-1-methylpropyl ester; 6-Methyl-1-isopropylergoline-8beta-carboxylic acid 2-hydroxy-1-methylpropyl ester; 6-methyl-1-(1-methylethyl)ergoline-8beta-carboxylic acid 2-hydroxy-1-methylpropyl ester; Ergoline-8-carboxylic acid, 6-methyl-1-(1-methylethyl)-, 2-hydroxy-1-m
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H32N2O3
|
|||
| Canonical SMILES |
CC(C)N1C=C2CC3C(CC(CN3C)C(=O)OC(C)C(C)O)C4=C2C1=CC=C4
|
|||
| InChI |
1S/C23H32N2O3/c1-13(2)25-12-16-10-21-19(18-7-6-8-20(25)22(16)18)9-17(11-24(21)5)23(27)28-15(4)14(3)26/h6-8,12-15,17,19,21,26H,9-11H2,1-5H3/t14?,15?,17-,19-,21-/m1/s1
|
|||
| InChIKey |
JQYLIGHHVGCTPR-LYRPIDSHSA-N
|
|||
| CAS Number |
CAS 32896-53-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2A receptor (HTR2A) | Target Info | Antagonist | [1], [2], [3], [4] |
| 5-HT 2B receptor (HTR2B) | Target Info | Antagonist | [4] | |
| 5-HT 2C receptor (HTR2C) | Target Info | Antagonist | [1], [2], [3], [4] | |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Serotonergic synapse | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | 5HT2 type receptor mediated signaling pathway | |||
| Reactome | Serotonin receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Serotonin Receptor 2 and STAT3 Signaling | ||||
| SIDS Susceptibility Pathways | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The 5-hydroxytryptamine2A receptor is involved in (+)-norfenfluramine-induced arterial contraction and blood pressure increase in deoxycorticostero... J Pharmacol Exp Ther. 2007 May;321(2):485-91. | |||
| REF 2 | Some studies on the 5-hydroxytryptamine receptors in the isolated rat uterus. Afr J Med Med Sci. 2002 Dec;31(4):361-5. | |||
| REF 3 | The fenfluramine metabolite (+)-norfenfluramine is vasoactive. J Pharmacol Exp Ther. 2004 May;309(2):845-52. | |||
| REF 4 | p-Chloroamphetamine, a serotonin-releasing drug, elicited in rats a hyperglycemia mediated by the 5-HT1A and 5-HT2B/2C receptors. Eur J Pharmacol. 1998 Oct 23;359(2-3):185-90. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.